Focus on drug discovery failure. Development of Risvodetinib for Parkinson’s disease was halted following disappointing Phase II results. The drug, which is a potent, brain-penetrant c-Abl inhibitor, was being developed by Inhibikase Therapeutics which reported its findings in an SEC filing. The drug met safety and tolerability requirements but failed to demonstrate significant efficacy.
Focus Biomolecules can supply Risvodetinib for research applications. Contact us for more information.
